ArticleInfection and drug resistance2026
Clinical Distribution and Antimicrobial Resistance Characteristics of
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objective: To describe the clinical distribution and antimicrobial susceptibility profile of Methods: This single-center retrospective cohort study included 112 consecutive patients with clinically adjudicated otorhinolaryngological infection and culture-confirmed Results: The most common sites were the external ear canal/external ear (31.2%), middle ear/mastoid (25.0%), and nasal cavity/paranasal sinuses (21.4%). MDR was identified in 37 patients (33.0%). The highest susceptibility percentages were observed for colistin/polymyxin B (95.5%), amikacin (84.8%), and piperacillin-tazobactam (79.5%), whereas the highest resistance percentages were observed for aztreonam (32.1%), levofloxacin (27.7%), and ceftazidime (24.1%). Recent carbapenem exposure (adjusted odds ratio [aOR] 5.09, 95% confidence interval [CI] 1.22-21.19), postoperative indwelling devices/drainage (aOR 4.81, 95% CI 1.81-12.83), and hospital-acquired infection (aOR 2.52, 95% CI 1.02-6.23) were independently associated with MDR. MDR infections were associated with longer hospitalization, higher C-reactive protein levels, more antimicrobial regimen modifications, and lower clinical success. Conclusion: This study provides specialty- and region-specific evidence that MDR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.